LivaNova Q4 revenue $321.8M (+6.8% organic); FY2025 adjusted EPS guidance $3.65-$3.75

LivaNova PLC

2024-FY EPS reported $1.16 revenue$1,253,437,000

Q4 revenue $321.8M (+6.8% organic YoY); GAAP EPS $1.02, adjusted EPS $0.81.
FY2024 revenue $1.25B (+10.7% organic); GAAP EPS $1.16, adjusted EPS $3.38.
FY2025 guidance: constant-currency revenue growth 5-6%, adjusted EPS $3.65-$3.75, adjusted FCF $135-155M.
OSPREY sleep apnea study met primary safety and efficacy endpoints at 6 months; RECOVER depression study publications support VNS Therapy.
Natalia Kozmina appointed Chief Human Resources Officer in January 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.